ArticleMolecular metabolism2026
Hepatic HuR modulates glucose metabolism through the C/EBPβ/PCK1 pathway.
Article in Molecular metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver plays a pivotal role in glucose homeostasis, adapting to metabolic challenges through transcriptional and post-transcriptional mechanisms. While the RNA-binding protein HuR/ELAVL1 is known to regulate mRNA stability during development and stress, its role in adult liver energy metabolism remains largely unexplored. Here, we demonstrate that hepatic HuR expression is dynamically induced in response to diverse metabolic challenges, including in vivo models of fasting (glucagon stimulation), caloric restriction, high-fat diet (HFD), and type 2 diabetes (T2D). Mechanistically, HuR modulates Cebpb mRNA, thereby enhancing the expression of phosphoenolpyruvate carboxykinase (PCK1), a key gluconeogenic enzyme. This interaction was assessed by in vivo immunoprecipitation and sequencing of ribonucleoprotein (RNP) complexes from mouse liver, which confirmed Cebpb modulation HuR-dependent. Silencing hepatic Elavl1 via siRNA delivery downregulated the C/EBPβ/PCK1 axis, increased glycogen synthesis, and improved hepatic insulin sensitivity and glycemic control. Furthermore, this increase in hepatic glycogen content led to reduced food intake, adiposity, and body weight in both healthy and diabetic mice. Collectively, our in vivo findings uncover HuR as a central post-transcriptional regulator of glucose metabolism in the liver and position it as a promising therapeutic target in metabolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.